|
1
|
Platell CF: Changing patterns of
recurrence after treatment for colorectal cancer. Int J Colorectal
Dis. 22:1223–1231. 2007.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Coffey JC, Wang JH, Smith MJ,
Bouchier-Hayes D, Cotter TG and Redmond HP: Excisional surgery for
cancer cure: Therapy at a cost. Lancet Oncol. 4:760–768.
2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Kumara HM, Feingold D, Kalady M, Dujovny
N, Senagore A, Hyman N, Cekic V and Whelan RL: Colorectal resection
is associated with persistent proangiogenic plasma protein changes:
Postoperative plasma stimulates in vitro endothelial cell growth,
migration, and invasion. Ann Surg. 249:973–977. 2009.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Shantha Kumara HM, Myers EA, Herath SA,
Jang JH, Njoh L, Yan X, Kirchoff D, Cekic V, Luchtefeld M and
Whelan RL: Plasma monocyte chemotactic protein-1 remains elevated
after minimally invasive colorectal cancer resection. World J
Gastrointest Oncol. 6:413–419. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shantha Kumara HM, Gaita D, Miyagaki H,
Yan X, Hearth SA, Njoh L, Cekic V and Whelan RL: Plasma chitinase
3-like 1 is persistently elevated during first month after
minimally invasive colorectal cancer resection. World J
Gastrointest Oncol. 8:607–614. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kumara HMCS, Bellini GA, Caballero OL,
Herath SAC, Su T, Ahmed A, Njoh L, Cekic V and Whelan RL:
P-Cadherin (CDH3) is overexpressed in colorectal tumors and has
potential as a serum marker for colorectal cancer monitoring.
Oncoscience. 4:139–147. 2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shantha Kumara HM, Kirman I, Feingold D,
Cekic V, Nasar A, Arnell T, Balik E, Hoffman A, Baxter R, Conte S
and Whelan RL: Perioperative GMCSF limits the proangiogenic plasma
protein changes associated with colorectal cancer resection. Eur J
Surg Oncol. 35:295–301. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Carter JJ, Feingold DL, Oh A, Kirman I,
Wildbrett P, Stapleton G, Asi Z, Fowler R, Bhagat G, Huang EH, et
al: Perioperative immunomodulation with Flt3 kinase ligand or a
whole tumor cell vaccine is associated with a reduction in lung
metastasis formation after laparotomy in mice. Surg Innov.
13:41–47. 2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Smith I, Robertson J, Kilburn L, Wilcox M,
Evans A, Holcombe C, Horgan K, Kirwan C, Mallon E, Sibbering M, et
al: Long-term outcome and prognostic value of Ki67 after
perioperative endocrine therapy in postmenopausal women with
hormone-sensitive early breast cancer (POETIC): An open-label,
multicentre, parallel-group, randomised, phase 3 trial. Lancet
Oncol. 21:1443–1454. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
O'Reilly MS, Holmgren L, Shing Y, Chen C,
Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH and Folkman J:
Angiostatin: A novel angiogenesis inhibitor that mediates the
suppression of metastases by a Lewis lung carcinoma. Cell.
79:315–328. 1994.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kirman I, Cekic V, Poltaratskaia N, Asi Z,
Bessler M, Huang EH, Forde KA and Whelan RL: Plasma from patients
undergoing major open surgery stimulates in vitro tumor growth:
Lower insulin-like growth factor binding protein 3 levels may, in
part, account for this change. Surgery. 132:186–192.
2002.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Allendorf JD, Bessler M, Horvath KD,
Marvin MR, Laird DA and Whelan RL: Increased tumor establishment
and growth after open vs. laparoscopic surgery in mice may be
related to differences in postoperative T-cell function. Surg
Endosc. 13:233–235. 1999.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Shantha Kumara HM, Cabot JC, Yan X, Herath
SA, Luchtefeld M, Kalady MF, Feingold DL, Baxter R and Whelan RL:
Minimally invasive colon resection is associated with a persistent
increase in plasma PlGF levels following cancer resection. Surg
Endosc. 25:2153–2158. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Shantha Kumara HM, Tohme ST, Herath SA,
Yan X, Senagore AJ, Nasar A, Kalady MF, Baxter R and Whelan RL:
Plasma soluble vascular adhesion molecule-1 levels are persistently
elevated during the first month after colorectal cancer resection.
Surg Endosc. 26:1759–1764. 2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shantha Kumara HM, Gaita DJ, Miyagaki H,
Yan X, Herath SA, Cekic V and Whelan RL: Minimally invasive
colorectal resection is associated with significantly elevated
levels of plasma matrix metalloproteinase 3 (MMP-3) during the
first month after surgery which may promote the growth of residual
metastases. Surg Endosc. 28:3322–3328. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Shantha Kumara HMC, Pettke E, Shah A, Yan
X, Cekic V, Downing MA, Gandhi ND and Whelan RL: Plasma levels of
the proangiogenic protein CXCL16 remains elevated for 1 month after
minimally invasive colorectal cancer resection. World J Surg Oncol.
16(132)2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shantha Kumara HMC, Sutton E, Bellini GA,
Yan X, Cekic V, Gandhi ND and Whelan RL: Plasma interleukin-8
levels are persistently elevated for 1 month after minimally
invasive colorectal resection for colorectal cancer. Mol Clin
Oncol. 8:471–476. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Belizon A, Balik E, Horst P, Feingold D,
Arnell T, Azarani T, Cekic V, Skitt R, Kumara S and Whelan RL:
Persistent elevation of plasma vascular endothelial growth factor
levels during the first month after minimally invasive colorectal
resection. Surg Endosc. 22:287–297. 2008.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shantha Kumara HM, Kirchoff D, Naffouje S,
Grieco M, Herath SA, Dujovny N, Kalady MF, Hyman N, Njoh L and
Whelan RL: Plasma from the second and third weeks after open
colorectal resection for cancer stimulates in vitro endothelial
cell growth, migration, and invasion. Surg Endosc. 26:790–795.
2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shantha Kumara HM, Grieco MJ, Caballero
OL, Su T, Ahmed A, Ritter E, Gnjatic S, Cekic V, Old LJ, Simpson
AJ, et al: MAGE-A3 is highly expressed in a subset of colorectal
cancer patients. Cancer Immun. 12(16)2012.PubMed/NCBI
|
|
21
|
Shantha Kumara H, Kirchoff D, Caballero
OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ,
Cordon-Cardo C and Whelan RL: Expression of the cancer testis
antigen IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a
specific immunotherapy target. Oncoscience. 2:607–614.
2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Shetty S and Idell S: FIBRINOLYSIS |
Plasminogen Activator and Plasmin. In: Encyclopedia of Respiratory
Medicine. Laurent GJ and Shapiro SD (eds). Academic Press,
pp205-210, 2006.
|
|
23
|
Wilkinson HN and Hardman MJ: . Wound
healing: Cellular mechanisms and pathological outcomes. Open Biol.
10(200223)2020.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Isogai C, Laug WE, Shimada H, Declerck PJ,
Stins MF, Durden DL, Erdreich-Epstein A and DeClerck YA:
Plasminogen activator inhibitor-1 promotes angiogenesis by
stimulating endothelial cell migration toward fibronectin. Cancer
Res. 61:5587–5594. 2001.PubMed/NCBI
|
|
25
|
Dellas C and Loskutoff DJ: Historical
analysis of PAI-1 from its discovery to its potential role in cell
motility and disease. Thromb Haemost. 93:631–640. 2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Angenete E, Langenskiöld M, Palmgren I,
Falk P, Oresland T and Ivarsson ML: uPA and PAI-1 in rectal
cancer-relationship to radiotherapy and clinical outcome. J Surg
Res. 153:46–53. 2009.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Lu JJ, Guo H, Gao B, Zhang Y, Lin QL, Shi
J, Liu JJ and Liu J: Prognostic value of urokinase plasminogen
activator system in non-small cell lung cancer: A systematic review
and meta-analysis. Mol Clin Oncol. 8:127–132. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Harbeck N, Thomssen C, Berger U, Ulm K,
Kates RE, Höfler H, Jänicke F, Graeff H and Schmitt M: Invasion
marker PAI-1 remains a strong prognostic factor after long-term
follow-up both for primary breast cancer and following first
relapse. Breast Cancer Res Treat. 54:147–157. 1999.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Harbeck N, Schmitt M, Meisner C, Friedel
C, Untch M, Schmidt M, Sweep CG, Lisboa BW, Lux MP, Beck T, et al:
Ten-year analysis of the prospective multicentre Chemo-N0 trial
validates American Society of Clinical Oncology (ASCO)-recommended
biomarkers uPA and PAI-1 for therapy decision making in
node-negative breast cancer patients. Eur J Cancer. 49:1825–1835.
2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Suh YS, Yu J, Kim BC, Choi B, Han TS, Ahn
HS, Kong SH, Lee HJ, Kim WH and Yang HK: Overexpression of
plasminogen activator inhibitor-1 in advanced gastric cancer with
aggressive lymph node metastasis. Cancer Res Treat. 47:718–726.
2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Berger DH: Plasmin/plasminogen system in
colorectal cancer. World J Surg. 26:767–771. 2002.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nielsen HJ, Christensen IJ, Sørensen S,
Moesgaard F and Brünner N: Preoperative plasma plasminogen
activator inhibitor type-1 and serum C-reactive protein levels in
patients with colorectal cancer. The RANX05 colorectal cancer study
group. Ann Surg Oncol. 7:617–623. 2000.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chen H, Peng H, Liu W, Sun Y, Su N, Tang
W, Zhang X, Wang J, Cui L, Hu P and Liu S: Silencing of plasminogen
activator inhibitor-1 suppresses colorectal cancer progression and
liver metastasis. Surgery. 158:1704–1713. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Desborough JP: The stress response to
trauma and surgery. Br J Anaesth. 85:109–117. 2000.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kany S, Vollrath JT and Relja B: Cytokines
in inflammatory disease. Int J Mol Sci. 20(6008)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Shantha Kumara H, Yan XH, Pettke E, Cekic
V, Gandhi ND, Bellini GA and Whelan RL: Plasma and wound fluid
levels of eight proangiogenic proteins are elevated after
colorectal resection. World J Gastrointest Oncol. 11:470–488.
2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Chan JC, Duszczyszyn DA, Castellino FJ and
Ploplis VA: Accelerated skin wound healing in plasminogen activator
inhibitor-1-deficient mice. Am J Pathol. 159:1681–1688.
2001.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Maquerlot F, Galiacy S, Malo M, Guignabert
C, Lawrence DA, d'Ortho MP and Barlovatz-Meimon G: Dual role for
plasminogen activator inhibitor type 1 as soluble and as
matricellular regulator of epithelial alveolar cell wound healing.
Am J Pathol. 169:1624–1632. 2006.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Devy L, Blacher S, Grignet-Debrus C, Bajou
K, Masson V, Gerard R.D, Gils A, Carmeliet G, Carmeliet P, Declerck
PJ, et al: The pro- or antiangiogenic effect of plasminogen
activator inhibitor 1 is dose dependent. FASEB J. 16:147–154.
2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Bajou K, Peng H, Laug WE, Maillard C, Noel
A, Foidart JM, Martial JA and DeClerck YA: Plasminogen activator
inhibitor-1 protects endothelial cells from FasL-mediated
apoptosis. Cancer Cell. 14:324–334. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Stefansson S, Petitclerc E, Wong MK,
McMahon GA, Brooks PC and Lawrence DA: Inhibition of angiogenesis
in vivo by plasminogen activator inhibitor-1. J Biol Chem.
276:8135–8141. 2001.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Uchiyama T, Kurabayashi M, Ohyama Y,
Utsugi T, Akuzawa N, Sato M, Tomono S, Kawazu S and Nagai R:
Hypoxia induces transcription of the plasminogen activator
inhibitor-1 gene through genistein-sensitive tyrosine kinase
pathways in vascular endothelial cells. Arterioscler Thromb Vasc
Biol. 20:1155–1161. 2000.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Casimiro MC, Crosariol M, Loro E, Li Z and
Pestell RG: Cyclins and cell cycle control in cancer and disease.
Genes Cancer. 3:649–657. 2012.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Giacoia EG, Miyake M, Lawton A, Goodison S
and Rosser CJ: PAI-1 leads to G1-phase cell-cycle progression
through cyclin D3/cdk4/6 upregulation. Mol Cancer Res. 12:322–334.
2014.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Webb DJ, Thomas KS and Gonias SL:
Plasminogen activator inhibitor 1 functions as a urokinase response
modifier at the level of cell signaling and thereby promotes MCF-7
cell growth. J Cell Bio. 152:741–752. 2001.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Kwaan HC, Wang J, Svoboda K and Declerck
PJ: Plasminogen activator inhibitor 1 may promote tumour growth
through inhibition of apoptosis. Br J Cancer. 82:1702–1708.
2000.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Fang H, Placencio VR and DeClerck YA:
Protumorigenic activity of plasminogen activator inhibitor-1
through an antiapoptotic function. J Natl Cancer Inst.
104:1470–1484. 2012.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chen Y, Kelm RJ Jr, Budd RC, Sobel BE and
Schneider DJ: Inhibition of apoptosis and caspase-3 in vascular
smooth muscle cells by plasminogen activator inhibitor type-1. J
Cell Biochem. 92:178–188. 2004.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Rømer MU, Larsen L, Offenberg H, Brünner N
and Lademann UA: Plasminogen activator inhibitor 1 protects
fibrosarcoma cells from etoposide-induced apoptosis through
activation of the PI3K/Akt cell survival pathway. Neoplasia.
10:1083–1091. 2008.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Inoue M, Sawada T, Uchima Y, Kimura K,
Nishihara T, Tanaka H, Yashiro M, Yamada N, Ohira M and Hirakawa K:
Plasminogen activator inhibitor-1 (PAI-1) gene transfection
inhibits the liver metastasis of pancreatic cancer by preventing
angiogenesis. Oncol Rep. 14:1445–1451. 2005.PubMed/NCBI
|
|
51
|
Kubala MH and DeClerck YA: The plasminogen
activator inhibitor-1 paradox in cancer: A mechanistic
understanding. Cancer Metastasis Rev. 38:483–492. 2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Placencio VR and DeClerck YA: Plasminogen
activator inhibitor-1 in cancer: Rationale and insight for future
therapeutic testing. Cancer Res. 75:2969–2974. 2015.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Fortenberry YM: Plasminogen activator
inhibitor-1 inhibitors: A patent review (2006-present). Expert Opin
Ther Pat. 23:801–815. 2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Gomes-Giacoia E, Miyake M, Goodison S and
Rosser CJ: Targeting plasminogen activator inhibitor-1 inhibits
angiogenesis and tumor growth in a human cancer xenograft model.
Mol Cancer Ther. 12:2697–2708. 2013.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Mutoh M, Niho N, Komiya M, Takahashi M,
Ohtsubo R, Nakatogawa K, Ueda K, Sugimura T and Wakabayashi K:
Plasminogen activator inhibitor-1 (Pai-1) blockers suppress
intestinal polyp formation in Min mice. Carcinogenesis. 29:824–829.
2008.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Mashiko S, Kitatani K, Toyoshima M,
Ichimura A, Dan T, Usui T, Ishibashi M, Shigeta S, Nagase S, Miyata
T and Yaegashi N: Inhibition of plasminogen activator inhibitor-1
is a potential therapeutic strategy in ovarian cancer. Cancer Biol
Ther. 16:253–260. 2015.PubMed/NCBI View Article : Google Scholar
|
